Featured Content

William McGivney, PhD
National Health Policy Expert

Study Finds Cancer Guidelines Do Not Fully Meet IOM Standards

(U-M Health System) June 12, 2013 - Researchers at the University of Michigan Comprehensive Cancer Center looked at 169 cancer clinical practice guidelines for lung, breast, prostate and colorectal cancers and found that none of the guidelines fully met standards set in 2011 by the Institute of Medicine.

Commentary: In my life, I have learned with stark surety that “the perfect is the enemy of the good”! It was a noble...

 1 comments  Add a comment
 facebook share button  twitter share button  linkedin share button



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Industry-Backed Studies More Prominent at Meetings

(Reuters Health) June 18, 2013 - Studies that are funded by pharmaceutical companies or involve industry-backed scientists tend to be more prominent at cancer meetings than independent studies, a new report suggests.
read article »

Blood Tests Could Detect Sexually-Transmitted Oral Cancers

(Reuters) June 17, 2013 - Antibodies to a high-risk type of a virus that causes mouth and throat cancers when transmitted via oral sex can be detected in blood tests many years before onset of the disease, according to a World Health Organisation-led team of researchers.
read article »

Observation Is Safe, Cost-Saving in Low-Risk Prostate Cancer

(Dana-Farber) June 17, 2013 - Dana-Farber researchers find many men with low-risk, localized prostate cancers can safely choose observation instead of undergoing immediate treatment and have a better quality of life while reducing health care costs.
read press release »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Study Finds Cancer Guidelines Do Not Fully Meet IOM Standards (U-M Health System)

In my life, I have learned with stark surety that “the perfect is the enemy of the good”! It was a noble...posted by: William McGivney, PhD

Inhalation Therapy for Lung Cancer Shows Promise in Rutgers Study (Rutgers)

A challenge with the whole concept of inhalational anti-cancer therapy for lung cancer is that the overwhelming...posted by: H. Jack West, MD

Judge's Ruling Challenges US Transplant System (New York Times/Associated Press)

Easy to Set Policies: Can be Gut-Wrenching to Make Decisions Based on Policies The recent cases and arguments...posted by: William, McGivney, PhD

Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology (NASDAQ)

Quizartinib is clearly the most effective FLT-3 inhibitor that has been in clinical trials so far and that is clearly...posted by: Susan O'Brien, MD

Data Presented at 2013 ASCO Offers First Evidence that Long-Term Treatment with Jakafi® (ruxolitinib) May Stabilize or Reverse Bone Marrow Fibrosis, a Key Marker of Worsening Disease in Patients with Myelofibrosis (Daily Finance)

As the title suggests, this is the first data showing an actual reduction in bone marrow fibrosis over time in...posted by: Susan, O'Brien, MD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.



What clinical information presented at ASCO was of the most interest to oncologists?

To get a sense of the impact that the 2013 annual meeting of ASCO had on physicians, Encuity Research surveyed 100 oncologists who attended the event to see what they thought were the key themes and overall value of this year's meeting. Check out our blog to see the results of the survey.





OBR Job Board

Seattle Genetics

Advocacy Development Director
Advocacy Development Managers (4)

Novocure

Clinical Science Liaison
Medical Communications Specialist
Training Manager

Sarah Cannon

Home-based Clinical Research Associate

View all job listings here


KH_OMAUS_300x250

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
NKTR +9.28%
KERX +6.95%
GERN +4.43%
RNN -7.55%
CLSN -5.34%
TSRO -4.43%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: July 15, 2013
Company: Boehringer Ingelheim Pharmaceuticals
Product: afatinib (BIBW 2992)

Date: June / July 2013
Company: NewLink Genetics Corp.
Product: algenpantucel-L

Date: Q3 2013
Company: Antisense Pharma GmbH
Product: trabedersen

See All OBR Radar items»